BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 10794805)

  • 1. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
    Agarwala SS; Kirkwood JM
    Oncologist; 2000; 5(2):144-51. PubMed ID: 10794805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide for Treating Malignant Melanoma.
    Li RH; Hou XY; Yang CS; Liu WL; Tang JQ; Liu YQ; Jiang G
    J Coll Physicians Surg Pak; 2015 Sep; 25(9):680-8. PubMed ID: 26374366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
    Margolin K; Atkins B; Thompson A; Ernstoff S; Weber J; Flaherty L; Clark I; Weiss G; Sosman J; II Smith W; Dutcher P; Gollob J; Longmate J; Johnson D
    J Cancer Res Clin Oncol; 2002 Apr; 128(4):214-8. PubMed ID: 11935312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide: a novel oral alkylating agent.
    Danson SJ; Middleton MR
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide in malignant gliomas: current use and future targets.
    Villano JL; Seery TE; Bressler LR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
    Bael TE; Peterson BL; Gollob JA
    Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
    Conill C; Fernández-Ibiza J; Malvehy J; Puig S; Sánchez M; Castel T
    Med Clin (Barc); 2004 Mar; 122(11):413-5. PubMed ID: 15066248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of brain metastases of malignant melanoma with temozolomide.
    Biasco G; Pantaleo MA; Casadei S
    N Engl J Med; 2001 Aug; 345(8):621-2. PubMed ID: 11529230
    [No Abstract]   [Full Text] [Related]  

  • 9. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
    Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
    J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of temozolomide in pediatric brain tumors.
    Barone G; Maurizi P; Tamburrini G; Riccardi R
    Childs Nerv Syst; 2006 Jul; 22(7):652-61. PubMed ID: 16565851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
    Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
    Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide in malignant gliomas.
    Yung WK
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):27-34. PubMed ID: 10866347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action.
    Bei R; Marzocchella L; Turriziani M
    Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):172-87. PubMed ID: 20594183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
    Paul MJ; Summers Y; Calvert AH; Rustin G; Brampton MH; Thatcher N; Middleton MR
    Melanoma Res; 2002 Apr; 12(2):175-8. PubMed ID: 11930115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
    Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
    Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide as prophylaxis for melanoma brain metastases.
    Conill C; González-Cao M; Jorcano S; Puig S; Malvehy J; Martí R; Castel T
    Melanoma Res; 2004 Feb; 14(1):73-4. PubMed ID: 15091198
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete response of multiple melanoma brain metastases after treatment with temozolomide.
    Dvorak J; Melichar B; Zizka J; Hadzi-Nikolov D; Petera J
    Onkologie; 2004 Apr; 27(2):171-4. PubMed ID: 15138351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.